Volume 9 Supplement 2

AIDS Vaccine 2012

Open Access

Passive immunization with polyclonal anti-SHIV IgG: partial protection or increased acquisition of heterologous tier 2 SHIV – depending on IgG dose

  • AM Sholukh9,
  • NB Siddappa9,
  • V Shanmuganathan1,
  • SK Lakhashe9,
  • RA Rasmussen9,
  • JD Watkins9,
  • HK Vyas9,
  • MM Mukhtar9,
  • G Hemashettar1,
  • S Thorat9,
  • JK Yoon1,
  • F Villinger2,
  • FJ Novembre2,
  • G Landucci3,
  • DN Forthal3,
  • S Ratcliffe4,
  • M Robert-Guroff5,
  • V Polonis6,
  • DC Montefiori7,
  • HC Ertl8 and
  • RM Ruprecht9
Retrovirology20129(Suppl 2):P41

DOI: 10.1186/1742-4690-9-S2-P41

Published: 13 September 2012


While passively administered broadly neutralizing monoclonal antibodies (bnmAbs) prevented SHIV acquisition, polyclonal Abs with high neutralizing titers provided only moderate protection in primates.


We tested whether passive immunization with polyclonal IgG raised in rhesus monkeys (RMs) with chronic clade C SHIV infection, termed SHIVIG, could protect RMs against multiple low-dose intrarectal challenges with the R5 tier-2 SHIV-2873Nip carrying an HIV clade C envelope heterologous to the viruses/envelopes against which the IgG responses had been elicited. We compared in vitro SHIVIG characteristics with in vivo protection.


In vitro, SHIVIG demonstrated binding to SIV Gag, HIV Tat and Env of different clades, contained b12 and 4E10-like Abs and neutralized tier-1 and 2 viruses, including SHIV-2873Nip. NK-cell depletion decreased neutralizing activity in PBMC assays 20-fold. SHIVIG completely inhibited viral replication by ADCVI assay, but showed only 35% target-cell killing by ADCC assay.

Four groups of RMs were given SHIVIG at different doses: Group 1 (400 mg/kg), Group 2 (675 mg/kg), Group 3 (25 mg/kg) and Group 4 (none; virus-only control) followed by weekly low-dose challenges with SHIV-2873Nip. All controls and all SHIVIG-treated animals became systemically infected. RMs given 400 mg/kg of SHIVIG showed significantly lower peak viral RNA loads compared to controls. Surprisingly, single-genome analysis revealed a significant increase in the number of transmitted variants in Group 3 compared to controls (P=0.032), suggesting increased acquisition. Complement-mediated Ab-dependent enhancement of infection (C’-ADE) at low SHIVIG concentrations was observed in vitro.


Lack of protection and possibly increased acquisition has been reported for a passive immunization study that tested the efficacy of HIV hyperimmune globulin in preventing infection in Ugandan infants born to HIV-positive women (Onyango-Makumbi, JAIDS 2011). Thus, our primate model data paralleled clinical phase III results and suggest that polyclonal anti-HIV-1 Abs play a dual role upon virus encounter.

Authors’ Affiliations

Dana-Farber Cancer Institute
Yerkes National Primate Research Center and Emory University
Division of Infectious Disease, University of California Irvine
University of Pennsylvania
Vaccine Branch, NCI, NlH
The Military HIV Res. Program, Walter Reed Army Inst. of Research
Department of Surgery, Duke University School of Medicine
The Wistar Institute
Dana-Farber Cancer Institute/Harvard Medical School


© Sholukh et al; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.